APG Asset Management US’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-5,334
Closed -$2.16M – 177
2025
Q3
$2.16M Hold
5,334
– – 0.02% 100
2025
Q2
$2.41M Hold
5,334
– – 0.02% 92
2025
Q1
$2.59M Hold
5,334
– – 0.02% 95
2024
Q4
$2.15M Sell
5,334
-666
-11% -$309K 0.02% 96
2024
Q3
$2.82M Sell
6,000
-70,048
-92% -$33.6M 0.02% 85
2024
Q2
$35.8M Buy
76,048
+1,676
+2% +$727K 0.21% 61
2024
Q1
$31.3M Buy
74,372
+23,967
+48% +$10.1M 0.18% 66
2023
Q4
$20.5M Buy
+50,405
New +$18.6M 0.13% 67

Other funds holding VRTX

APG Asset Management US's VRTX Position: Q4 2025 in Review

APG Asset Management US sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 5,334 shares — an estimated $2.16M sold.

APG Asset Management US first reported a position in VRTX in Q4 2023 and held it in 8 quarters. The position peaked at $35.8M in Q2 2024. 1,674 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • APG Asset Management US reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • APG Asset Management US sold 5,334 Vertex Pharmaceuticals shares in Q4 2025, an estimated $2.16M.
  • APG Asset Management US first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • APG Asset Management US's Vertex Pharmaceuticals position peaked at $35.8M in Q2 2024.
  • 1,674 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on APG Asset Management US's 13F filing for Q4 2025, filed 12 Feb 2026.